CYP
vs
S
S&P/ASX 300
CYP
Over the past 12 months, CYP has significantly outperformed S&P/ASX 300, delivering a return of +44% compared to the S&P/ASX 300's +9% growth.
Stocks Performance
CYP vs S&P/ASX 300
Performance Gap
CYP vs S&P/ASX 300
Performance By Year
CYP vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cynata Therapeutics Ltd
Glance View
Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is engaged in the development and commercialization of a mesenchymal stem cell (MSC) technology for human therapeutic use, which the Company has branded as Cymerus. The Cymerus technology facilitates the manufacture of MSCs from a single donor and a single donation, which enables the development of therapeutic stem cell products. The firm's Cymerus platform stem cell technology is based upon stem cells known as mesenchymoangioblasts (MCAs). Its technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product. The Company’s lead product candidate, CYP-001, which has met all clinical endpoints and demonstrated safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase I trial.
